“Overall,” he said, “anti-tumor immune response
in all three of the tests are increased when you give
hormonal therapy plus sipuleucel-T in patients that
have biochemically recurrent prostate cancer without metastases.”
Q2 represented a corner turned. Q3 will be confirmation. Add automation, or Europe, or refinancing debt, or study updates, or.......and you will feel sorry you didn't buy more when you could. JMHO
I agree that Novartis is the most likely.
I think they'll partner first, with 25% equity stake--watch and wait and buyout if they like what they see.
My money's on Novartis (bought NJ plant; Watson strong connections; great interest in vaccines, etc.) but could create strong arguments for Sanofi, J and J or AGN as well.
But maybe MDVN, also.
Thanks for posting. You saved me the trouble. Long and strong and getting longer. The only "new" news is DENDREON BEAT ESTIMATES BY A LONG WAYS!
Thanks for posting. This will prove to be extremely important IMHO.
I didn't know that Bush was no longer associated with Prana.
Good to see that he is still supporting the science though.